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Abstract
Poor adherence remains a major barrier to achieving the clinical and public health benefits of 
antiretroviral drugs (ARVs). A systematic review and qualitative meta-synthesis was conduct to 
evaluate how ARV adverse drug reactions may influence ARV adherence. Thirty-nine articles 
were identified, and 33 reported that ARV adverse drug reactions decreased adherence and six 
studies found no influence. Visually noticeable adverse drug reactions and psychological adverse 
reactions were reported as more likely to cause non-adherence compared to other adverse drug 
reactions. Six studies reported a range of adverse reactions associated with EFV-containing 
regimens contributing to decreased adherence. Informing HIV-infected individuals about ARV 
adverse drug reactions prior to initiation, counselling about coping mechanisms, and experiencing 
the effectiveness of ARVs on wellbeing may improve ARV adherence.
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Introduction
Over 15 million HIV-infected individuals were on antiretroviral therapy (ART) by March 
2015 [1]. However, adherence to treatment remains a key challenge for HIV programs to 
achieve optimal health outcomes and viral suppression [2, 3]. The World Health 
Organization (WHO) defines treatment adherence as “the extent to which a person’s 
behavior-taking medications, following a diet and/or executing lifestyle changes corresponds 
with agreed recommendations from a health care provider” [4].
ARV adverse drug reactions are an important factor that influences adherence to ARV [5]. 
WHO defines an adverse drug reaction as “a response which is noxious and unintended, and 
which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of 
disease, or for modification of physiological function” [6]. Serious and/or long-term adverse 
drug reactions can affect adherence to the treatment regimen [7]. There is limited knowledge 
of how HIV-infected individuals perceive and experience adverse drug reactions to ARVs 
and how these perceptions and experiences may influence ARV adherence.
Qualitative synthesis focuses on in-depth interpretive explanation of a phenomenon and 
therefore enables deeper analysis of the complex, multi-faceted experiences of adverse drug 
reactions and its relation to ARV adherence. The aim of this qualitative synthesis was to 
systematically review and synthesize the qualitative literature examining how perception and 
experience of ARV adverse drug reactions influence drug adherence among HIV-infected 
individuals.
Methods
Search Strategy and Selection Criteria
In accordance with guidance from PRISMA checklist [8], ENTREQ [9], and meta-synthesis 
guidance from the Cochrane group [10], we used a comprehensive search strategy to identify 
all relevant studies in English (Search strategy available in supplement). The review protocol 
(CRD42015017265) was registered (www.crd.york.ac.uk/PROSPERO/). The following 
electronic journal and dissertation/thesis databases were searched from January 1st, 2000 
until February 21st 2015 (to limit to recent ARV drug regimens): CENTRAL (Cochrane 
Central Register of Controlled Trials), EMBASE, LILACS, PsycINFO, PubMed 
(MEDLINE), Web of Science/Web of Social Science, CINAHL, British Nursing Index and 
Archive, Social science citation index, AMED (Allied and Complementary Medicine 
Database), DAI (Dissertation Abstracts International), EPPI-Centre (Evidence for Policy and 
Practice Information and Coordinating Centre), ESRC (Economic and Social Research 
Council), Global Health (EBSCO), Anthrosource, and JSTOR. Conference proceedings 
including the Conferences on Retroviruses and Opportunistic Infections (CROI), 
International AIDS Conference (IAC), and alternating year International AIDS Society 
(IAS) clinical meetings were searched from their inception dates (1993, 1985 and 2001, 
respectively). References of included studies were checked and authors were contacted to 
provide additional information as required.
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Studies were selected that used qualitative research designs, including but not limited to 
ethnographic research, case studies, process evaluations, and mixed methods research. 
Studies also had to include qualitative data collection techniques (e.g., participant 
observation, in-depth interview, or focus group) and a qualitative data analysis approach 
(e.g., framework analysis, or thematic analysis). The review included studies that provided 
description and interpretation of the impact of adverse drug reactions on adherence for all 
HIV-infected individuals. We excluded studies that only used quantitative methods to 
investigate the same phenomenon.
Data Extraction
A health sciences librarian conducted the electronic searches and excluded duplicates. All 
titles were reviewed to examine relevance to the meta-synthesis topic. Two authors (HL & 
GM) independently reviewed abstracts and made a list of categories for exclusion, and then 
independently reviewed full text manuscripts and noted reasons for exclusion. Discordance 
between the two authors was resolved by a discussion with a third author (QM). Studies 
were reviewed for relevance based on adverse drug reaction’s impact on adherence, study 
design, main findings and interpretations of findings. (Fig. 1).
A data extraction form was designed specifically for this review. The characteristics 
extracted from each study included authors, year published, study design, location/
orientation of study, key populations and subgroups, age range, main findings, ARV drug 
regimen, and adverse drug reactions described.
Data Analysis
Prior to conducting the synthesis, each paper’s quality was assessed by both HL and GM 
using a seven scale criteria tool adapted from the critical appraisal skills programme (CASP) 
[11], which has been used in other reviews [12]. The CERQual approach was used to 
evaluate the certainty of the review finding [13]. This approach includes an assessment of 
methodological limitations, coherence, relevance, and adequacy (see the supplement for 
details), based on a guidance document from the Cochrane Collaboration Qualitative 
Methods Group [10, 13]. Thematic synthesis was adopted in the data analysis. A line-by-line 
coding of the findings of primary studies was conducted by HL and GM prior to organizing 
into related areas to construct descriptive themes. Analytical themes were developed based 
on the descriptive themes [14]. Pre-defined subgroup analyses were conducted among 
specific groups of adults, children and adolescents, and pregnant women. EFV was 
specifically chosen in the analysis because it has known adverse drug reactions and yet 
remains first-line therapy in WHO ARV guidelines.
Role of Funding Source
The WHO was a funding source for this study. The authors had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. The content 
of the article is solely the responsibility of the authors and does not necessarily represent the 
official views of WHO or the National Institutes of Health.
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Thirty-nine studies published after 2000 were included in the review. In the CASP 
assessment, most of the studies reached good quality with the highest score of 7 (17 studies) 
or 6 (14 studies), while some studies had medium score of 5 (4 studies) and low score of 4 or 
less (4 studies). Thirty-three out of 39 studies reported that perceived adverse ARV reactions 
decreased adherence [12, 15–46], whilst six studies [47–52] described no apparent 
relationship. Nineteen studies [12, 15–27, 29, 32, 36, 44, 47] were conducted in high-income 
countries, eight [30, 31, 33, 34, 41, 42, 46, 49] in middle-income countries, and twelve [28, 
35, 37–40, 43, 45, 48, 50–52] in low-income countries. (Countries—see Tables 1, 2).
The majority of the studies (34/39) sought the perspectives of HIV-infected adults. Two 
studies considered the views and experiences of children (aged 3–12) and their caregivers 
[24, 46] and one study of adolescents [45]. Two studies focused on pregnant women [16, 
36]. Three studies explored experiences of coping mechanisms for adverse drug reactions as 
a way of improving adherence [31, 38, 45]. Study characteristics have been summarized in 
Tables 1 and 2. Eight themes emerged in the thematic synthesis, which included three 
barriers (i.e., visually noticeable adverse drug reactions, psychological suffering, and 
Efavirenz (EFV)-containing regimens), three facilitators (i.e., prior knowledge of adverse 
ARV reactions, coping strategies, and self- perceived effectiveness of ARV), and subgroup 
analyses among populations of children, adolescents, and pregnant women.
Barriers
Visible Adverse Drug Reactions—Visible adverse drug reactions (e.g., body changes, a 
buffalo hump, excess sweating, darkening of the skin, body odor, hair loss, weight loss/gain, 
and skin rash) increased the risk of unintentional HIV disclosure and disturbed HIV-infected 
individuals’ daily routines. It led to low self-esteem and self-stigmatization among some 
HIV-infected individuals, and was felt to contribute to poor ARV adherence [15, 19, 21, 23, 
25, 28, 29, 32, 35, 38–40, 42, 45, 49, 50]. In several persistent cases, ARV adverse drug 
reactions caused HIV-infected individuals to undertake long treatment free vacations or quit 
treatment completely [15, 21, 23, 32, 49]. This finding has a CERQual high level of 
confidence.
For many participants on ARVs, adverse drug reactions were perceived to be detrimental to 
adherence [29]. Primary data from the reviewed articles include the following: “I have asked 
my doctor not to put me on any medication that would make me look like a freak. I would 
simply not take the drug if I developed a buffalo hump on my back” [23]. “I then had a skin 
rash to a point where I was so uncomfortable and sick that I stopped taking the medication” 
[21].
Psychological Suffering—Psychological suffering associated with adverse drug 
reactions (e.g., being reminded of being sick, delusional, a feeling of being killed by taking 
the drugs, and getting mad) were occasionally considered to be severe enough to contribute 
to poor adherence [17, 19, 20, 37, 40, 47, 49]. This finding has a CERQual high level of 
confidence.
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Primary data showed that some participants stopped taking ARVs because they realized that 
they were not psychologically prepared to take ARVs. For example, participants described: 
“Just the fact that I have to take it [medication(s)] and knowing that I’m going to have to 
take it for the rest of my life is having psychological effects, it’s causing trauma to my life 
right now” [19]. Participants generally used adjectives such as depressing, cranky, moody, 
sad, angry, guilty, irresponsible, nervous, anxious and afraid to describe their negative 
psychological problems related to ARVs [20].
Adverse Reactions Associated with EFV-Containing Regimens—Some people 
receiving EFV-containing regimens reported that neuropsychiatric adverse reactions (e.g., 
intense body heat, delusions, anxiety, intense dizziness, and nightmares) contributed to poor 
adherence [47–52]. This finding has a CERQual moderate level of confidence.
Participants described their pain and suffering related to EFV-associated adverse drug 
reactions: “The numbness crept up from my feet and spread out over my body. Just like with 
an electrical shock, the feet feel it the worst. During the night, my feet are so sore, numb, 
and swollen that I can hardly sleep. The pain is so constant. I can hardly close my eyes” 
[49]. “I can’t say that they have worked well because as you see now my face it has changed 
from its normal shape, I don’t know whether it is a type of drug or it is because I have spent 
some time on them” [50].
Facilitators
Prior Knowledge of Adverse ARV Reactions—When people receiving ART had prior 
knowledge of ARV adverse drug reactions, or had been informed in advance of potential 
adverse reactions and how to manage them, they felt these reactions were expected, normal 
and manageable, and therefore reported less non-adherence [35, 38, 48, 50]. This finding has 
a CERQual moderate level of confidence.
Participants described their experiences: “We were warned that some people would get drug 
reactions. This helped me not to worry when I fell sick” [38]. “That’s normal stuff” [48]. 
“Those things occur, and after a time they go away” [48]. For those participants who were 
informed about potential adverse effects of ARVs prior to treatment initiation, the reactions 
were not reported as reasons for non-adherence [48]. Participants wished they had been pre-
informed about the adverse effect profile at the initiation of treatment, so that they know 
how to manage these effects [35].
Coping Strategies—When people receiving ART developed coping strategies to cope 
with adverse events (e.g., drinking a lot of fluids and resting to reduce dizziness, or eating a 
snack or meal before swallowing pills to control nausea), they expressed good levels of 
adherence [31, 38, 45]. This finding has a CERQual moderate level of confidence.
Participants described how they dealt with adverse drug reactions: “I have abdominal 
distention. I felt so uncomfortable even if I only ate a little. I felt that the food was stuck 
there and was not digested. Taking some herb digestion medicine makes me feel better” 
[31]. A number of strategies were also employed to disguise visible adverse effects. For 
Li et al. Page 5













example, women reported wearing dark nail polish to cover darkened nails and wearing long 
sleeved clothes, ankle reaching skirts and trousers to cover body sores [38].
Perceived Effectiveness of ARVs—When people on ART experienced individual 
benefits of taking ARVs on their health (e.g., regaining physical strength, being more 
independent, and able to help with domestic work again), they achieved greater adherence 
independent of the adverse effects [30, 31, 45, 48]. This finding has a CERQual moderate 
level of confidence.
Participants described benefits of ARVs as a reason to adhere to medication as follows: “I 
say ARVs are medicine [e.g., effective medicine, not fake]. Because basing it off my health, 
I had lots of sores all over my body, on my arms, in my mouth, on my head, on my private 
parts, you understand? …After being started on the drugs, all those sores went away, my 
health status started to improve, and I was able to eat well. Until now after coming to test 
recently I had a CD4 of like 181. So it has risen well. It’s these meds [that do it], man” [48]. 
“I cannot live without these meds. If I did not take them, I might die very soon. The benefit 
of the meds is they enable me to survive a few more days. As patients, our lives have been 
shortened by HIV, but ART can extend our lives a little bit longer. Taking meds on time can 
prolong my life” [31].
Subgroup Analysis
Subgroup Analyses Among HIV-Infected Children and Adolescents—The 
experience of drug attributed adverse events (e.g., queasy feeling, vomiting, diarrhea, 
nausea, insatiable hunger, and skin sores) resulted in children’s refusal to take ARVs (e.g., 
coughing, gagging, and throwing it up) [24, 45, 46]. This finding has a CERQual moderate 
level of confidence.
For example, an adolescent said, “There is this one [pill] at night that makes you feel dizzy, 
that one bothersome a lot. I keep taking them, and then sometimes they […] provoke these 
scabs. Those others provoke wounds […], they damage your face. So these ARVs […] and 
my body don’t get along” [45].
Subgroup Analyses Among HIV-Infected Pregnant Women—Pregnant women 
perceived that the likelihood of their unborn baby suffering from ARV adverse effects was 
greater than the likelihood of their unborn baby acquiring HIV infection [36]. ARVs also 
worsened their pregnancy-associated nausea, hence they felt that ARVs did more harm than 
good [16, 36]. This finding has a CERQual low level of confidence.
For example, a woman described: “When you are pregnant, the thing about taking 
zidovudine (AZT) is that, it is so strong. Taking AZT is like taking drugs, it’s like taking 
marijuana or smoking crack…it’s like the baby is gonna be born with that in his system” 
[16].
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This synthesis identified 39 qualitative studies from diverse countries. Most of the studies 
supported that occurrence of ARV adverse drug reactions are associated with ARV non-
adherence. This is consistent with quantitative research demonstrating that adverse drug 
reactions contribute to poor adherence with treatment interruptions [53–56]. This synthesis 
formally evaluated the qualitative evidence and extended the literature in three ways: (1) 
proposing barriers that likely contribute to non-adherence (2) exploring facilitators to 
improve adherence, and (3) uncovering challenges among specific groups.
This qualitative synthesis explored potential neuropsychological mechanisms of subjective 
perceptions and experiences influencing ARV adherence. This is consistent with cross-
sectional data correlating subjective perceptions of ARVs and adherence [55, 56]. Cross-
sectional and cohort studies showed that depression, anxiety, negative cognitive and 
psychosocial functioning were frequently associated with poorer ARV adherence [57, 58]. 
This synthesis suggested that the experiences of taking ARVs were associated with 
significant psychological trauma and emotional suffering in some HIV-infected individuals. 
In particular, the trauma and constraints were usually related to being on a lifelong therapy 
associated with HIV infection. Also, visually noticeable adverse drug reactions could disturb 
daily routines and threaten HIV disclosure and embarrassment in public, which might in turn 
increase psychological and emotional burden. This suffering may further exacerbate self-
stigmatization and further decrease the self-esteem of HIV-infected individuals. When this 
suffering is not effectively addressed, it may contribute to ARV non-adherence.
Even though some ARV drugs (e.g., stavudine) has been recommended to be phased out 
[59]. This qualitative synthesis highlighted this concern and provided descriptions of adverse 
drug reactions related to EFV-containing regimens contributing to poor adherence. This is 
consistent with several quantitative meta-analysis demonstrating the association between 
EFV use and central nervous system (CNS) toxicity [60] and treatment non-adherence [61]. 
Shubber and colleagues’ systematic review described that around a third of people using 
EFV experienced CNS adverse reactions (e.g., dizziness, abnormal dreams) with variable 
degree of severity, which are usually mild and transient [62]. However, Shubber and 
colleagues’ review showed that compared to nevirapine, EFV was associated with a lower 
frequency of severe adverse reactions, particularly in treatment discontinuation among both 
adult and children populations [62]. A recent review [63] on comparative safety of EFV and 
impact of CNS adverse events showed 90 % of patients remaining on EFV (78 weeks). Even 
though the relative risk of treatment discontinuation due to EFV-related adverse events was 
higher than that related to other 1st line options (e.g., tenofovir disoproxil fumarate, 
abacavir, dolutegravir, raltegravir), the absolute differences were low (<5 %) [63]. Although 
the overall frequency of EFV adverse medication reactions remains rare, our findings 
suggest that EFV-containing regimens are perceived by PLWH as related to adverse 
reactions influencing their lives, appearance, and well-being.
Another important finding of this qualitative synthesis is that the HIV-infected individuals’ 
experience, perception, understanding, and knowledge of adverse drug reactions were 
related to ARV adherence. When people receiving ART experienced ARVs maintaining their 
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health effectively, had knowledge of adverse ARV reactions, and practiced coping strategies 
to manage these reactions, they were more likely on adherence. This is consistent with 
previous quantitative studies that having knowledge about adverse drug reactions, adherence 
self-efficacy, self-management, and individual strategies for fitting medication into daily 
routines were associated with ARV adherence [64, 65]. However, researchers also argued 
that extensive communicating about potential adverse medication reactions may increase the 
likelihood of a patient developing those reactions [66]. A simplified and structured 
informing approach about potential adverse drug reactions to ARV is needed.
This qualitative synthesis found very limited studies considering perspectives of children, 
adolescent, and pregnant women, and the findings were in moderate and low confidence 
levels respectively. For children and adolescents, refusal of ARVs or doses skipping were 
related to pediatric adherence barriers, such as feeling sick and needing a break [67], 
palatability of medication, large medication volumes, and limited treatment options [68, 69]. 
For pregnant women and women with history of childbirth, some important issues were 
emerging that they perceived ARVs as medically powerful and full of potential adverse 
effects, which made these women felt that ARVs did more harm than good. For this specific 
group of women, ARV adherence became more complicated.
This qualitative synthesis is subject to some limitations. First, some of the reviewed articles 
are weak in research design or have incomplete reporting. However, we evaluated the quality 
of individual studies and this quality assessment was reflected in the overall confidence 
assessment using CERQual. Second, most of the reviewed articles emphasized adults with 
HIV and few specifically focused on children, adolescents or pregnant women. It is therefore 
difficult to generalize the findings to other specific sub populations. Third, our qualitative 
synthesis only provided subjective interpretation of the relationship between patient 
attributed adverse drug reactions and ARV non-adherence and causal pathways could only 
be inferred.
Despite these limitations, this synthesis found that visually noticeable drug reactions, 
emotional and psychological suffering, and EFV-containing regimens may be related to non-
adherence for HIV-infected individuals. This synthesis also found that improved knowledge 
and understanding of adverse ARV reactions, experiencing the health benefits of ARVs, and 
strategies of coping and self-management were practically important in addressing the 
problem of ARV non-adherence caused by adverse drug reactions. It’s therefore important to 
provide HIV-infected individuals tailored counselling to enhance knowledge and 
understanding of adverse ARV reactions and to train and support people receiving ART how 
to adopt multiple strategies to deal with these reactions. Moreover, this synthesis provided 
directions for future studies. Vulnerable children, adolescents, and pregnant women are still 
far under studied in the qualitative literature on their experience and perception related to 
adherence of ARVs. Future qualitative studies should focus on exploring subjective 
experiences and perceptions of ARV adverse drug reactions and strategies being used to 
manage these reactions from the perspective of children, adolescents, and pregnant women.
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Table 2
Summary of study characteristics
No. of studies Percentage (%)
Year of publication
 2000–2004 8 20.5
 2005–2009 12 30.8
 2010–2015 19 48.7
Study location (countries)
 High income 19 48.7
 Middle income 8 20.5
 Low income 12 30.8
HIV-infected population
 Children 2 5.1
 Adolescents 1 2.6
 Pregnant women 2 5.1
 Adults 34 87.2
Study quality
 High 31 79.5
 Medium 7 17.9
 Low 1 2.6
Study method
 Interviews 25 64.1
 Focus groups 12 30.8
 Mixed methods 2 5.1
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